Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03240809 · ClinicalTrials.gov registry record · Phase 4
An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects
A Phase 4 study of Psoriasis, sponsored by Bausch Health Americas.
- Active
- Registry status
- Phase 4
- Development phase
- 2
- Enrollment target
- 5
- Study locations
NCT03240809: Active Phase 4 study of Psoriasis, sponsored by Bausch Health Americas.
NCT03240809 is a Phase 4 study of Psoriasis that is active but no longer recruiting, run by Bausch Health Americas. The registered enrollment target is 2 participants, below the 489-participant average among 125 other Psoriasis trials with a reported enrollment target (100% lower). The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03240809, a Phase 4 study of Psoriasis, is active but no longer recruiting, sponsored by Bausch Health Americas.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 2 participants
- Enrollment target
- 5
- Study locations
Study Summary
An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects
Primary Outcome
maximum (or peak) serum concentration that drug achieves in the body after drug has been administrated and prior to the administration of a second dose
Conditions Studied
Interventions
- BIOLOGICAL Brodalumab
Study Locations (5)
Florida
- Bausch Site 002 - Miami
- Bausch Site 004 - Miami
Nevada
- Bausch Site 005 - Henderson
- Bausch Site 001 - Las Vegas
California
- Bausch Site 003 - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2020-01-24 |
| Est. Completion | 2029-06 |
| Phase | Phase 4 |
What the registry record for NCT03240809 still lists
NCT03240809 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 489-participant average among 125 other Psoriasis trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which Brodalumab is the first listed.
NCT03240809 lists 5 locations in 3 states (Florida, Nevada, California).
Frequently Asked Questions
What is clinical trial NCT03240809 about?
NCT03240809 is a clinical study titled "An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects". An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects
What is the current status of trial NCT03240809?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 2 participants. The study started on 2020-01-24. Estimated completion is 2029-06.
What conditions does trial NCT03240809 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT03240809?
The interventions under investigation include: Brodalumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03240809?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03240809 being conducted?
This trial has 5 study locations across California, Florida, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03240809's enrollment target sits among peer trials
2 126th of 125 the lowest of 125 other Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Duobrii in Combination With Biologics
RECRUITING · Phase 4
-
Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics
RECRUITING · Phase 4
-
ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.
RECRUITING · Phase 4
-
A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis
RECRUITING · Phase 4
-
Taltz in Combination With Enstilar for Psoriasis
RECRUITING · Phase 4
-
A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants With Plaque Psoriasis
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI